New Risk • May 13
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$6.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.2m free cash flow). Share price has been highly volatile over the past 3 months (39% average weekly change). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (339% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$3.24m market cap). Announcement • Apr 22
Wenzhao Lu acquired Avalon RT9 Properties, LLC from Avalon GloboCare Corp. (NasdaqCM:ALBT) for $9 million. Wenzhao Lu acquired Avalon RT9 Properties, LLC from Avalon GloboCare Corp. (NasdaqCM:ALBT) for $9 million on February 18, 2026. The purchase price of approximately $9 million comprised of (i) $3.158078 million in cash previously advanced by Wenzhao Lu and applied toward the purchase price; and (ii) the assumption and satisfaction in full of the approximately $5.9 million outstanding mortgage balance.
Wenzhao Lu completed the acquisition of Avalon RT9 Properties, LLC from Avalon GloboCare Corp. (NasdaqCM:ALBT) on February 18, 2026. Announcement • Apr 18
Avalon GloboCare Corp Receives Notice of Non-Compliance with Nasdaq Minimum Bid Price Listing Rule On April 15, 2026, Avalon GloboCare Corp. (the Company) was notified (the Notification Letter) by The Nasdaq Stock Market, LLC (Nasdaq) that it is not in compliance with the minimum bid price requirements set in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common stock between March 1, 2026 to April 14, 2026, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Capital Market and, at this time, the common stock will continue to trade on The Nasdaq Capital Market under the symbol ALBT. The Notification Letter provides that the Company has 180 calendar days, or until October 12, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company's common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by October 12, 2026, an additional 180 days may be granted to regain compliance, so long as the Company meets The Nasdaq Capital Market continued listing requirement for market value of publicly-held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum closing bid price requirement and notifies Nasdaq in writing of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then Nasdaq will notify the Company of its determination to delist the Company's common stock, at which point the Company will have an opportunity to appeal the delisting determination to a Hearings Panel. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules. Announcement • Apr 04
Avalon GloboCare Corp., Annual General Meeting, Jun 09, 2026 Avalon GloboCare Corp., Annual General Meeting, Jun 09, 2026. Announcement • Feb 27
Avalon GloboCare Corp. announced that it expects to receive $3.250001 million in funding Avalon GloboCare Corp. announces that it has entered into definitive agreements to issue 6,372,550 shares at a price of $0.51 per share for gross proceeds of $3,250,000.5 on February 26, 2026. Series A-1 warrants to purchase up to an aggregate of 6,372,550 shares of common stock and Series A-2 warrants to purchase up to an aggregate of 6,372,550 shares of common stock, at a purchase price of $0.51 per share and associated warrants in a private placement priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $0.51 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. The Series A-1 warrants will expire five years from the date of stockholder approval and the Series A-2 warrants will expire eighteen months from the date of stockholder approval. The offering is expected to close on or about February 27, 2026. he securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants sold in the offering. Announcement • Jan 23
YOOV Group Holding Limited cancelled the acquisition of Avalon GloboCare Corp. (NasdaqCM:ALBT) in a reverse merger transaction. YOOV Group Holding Limited entered into a letter of intent to acquire Avalon GloboCare Corp. (NasdaqCM:ALBT) in a reverse merger transaction on November 27, 2024. YOOV Group Holding Limited entered into a definitive merger agreement to acquire Avalon GloboCare Corp. (NasdaqCM:ALBT) in a reverse merger transaction on March 7, 2025. Under the terms of the merger agreement, subject to stockholder approval, on a pro forma basis, post-merger Avalon equityholders are expected to collectively own between approximately 2.5% to 2.2% and YOOV equityholders are expected to collectively own between approximately 97.5%, or 97.8% of the common stock of the combined company on a pro forma basis. The combined company is expected to operate under the name YOOV, Inc. and expected to continue trading on The Nasdaq Capital Market under the symbol “YOOV”. Upon termination of the Merger Agreement under specified circumstances, Avalon may be required to pay YOOV a termination fee of $1 million; however, YOOV is not required to pay Avalon a termination fee. Following the merger, Phil Wong will become Chairman, Chief Executive Officer, and President. The merger agreement provides that the board of directors of the combined company will be composed of seven members, with five members initially designated by YOOV and two members initially designated by Avalon.
The transaction is subject to certain closing conditions, including, among other things, (i) approval of the Avalon Stockholder Matters by the requisite Avalon stockholders, (ii) adoption and approval of the Merger Agreement, and the transactions contemplated thereby, by the requisite YOOV shareholders, (iii) the effectiveness of the Registration Statement (iv) the listing of the Avalon Common Stock issuable in connection with the Merger on Nasdaq, (v) all approvals from any Governmental Authority necessary to consummate the transaction and (vi) a written resignation for each of the officers and directors of Avalon GloboCare who are not going to continue as officers or directors of Avalon GloboCare after the Closing and approval by the Nasdaq Stock Market of the listing of YOOV following the closing of the Merger. The merger agreement has been unanimously approved by the boards of directors of both companies. The transaction is expected to be completed in the third quarter of 2025. As of September 8, 2025, the transaction is expected to close in Q4 2025.
Steven Skolnick and Annie Nazarian Davydov of Lowenstein Sandler LLP acted as legal advisor for Avalon GloboCare Corp. Joseph M. Lucosky, Scott Linsky and Ian Liao of Lucosky Brookman LLP acted as legal advisor for YOOV Group Holding Limited. Vstock Transfer, LLC acted as transfer agent to Avalon. Roth Capital Partners acted as the exclusive financial advisor and provided fairness opinion to Avalon in connection with the merger. Roth agreed to receive a fee of $100,000 upon the delivery of the Roth Fairness Opinion.
YOOV Group Holding Limited cancelled the acquisition of Avalon GloboCare Corp. (NasdaqCM:ALBT) in a reverse merger transaction on January 21, 2026. Announcement • Jan 22
Avalon GloboCare Corp. Subsidiary, Avalon Quantum AI LLC Files AI Patent Targeting Compliance-Ready Automated Video Commentary Avalon GloboCare Corp. announced that its subsidiary, Avalon Quantum AI LLC, has filed a U.S. Provisional patent application covering a new class of evidence-constrained generative AI systems designed to produce automated video commentary with built-in source traceability and auditability. The provisional patent application, titled "Systems and Methods for Evidence-Constrained, Audience-Adaptive Generation of Automated Commentary Videos" (U.S. Provisional Patent Application No. 63/961,889), was filed on January 16, 2026. The filing describes a proprietary AI architecture intended to address a structural risks ingenerative media markets: the inability to reliably verify, audit, and defend AI-generated outputs at scale. Unlike conventional generative video systems, the disclosed technology enforces an evidence-linked generation framework in which every narrative asserting within a rendered video must be explicitly supported by underlying source materials. The system constructs structured evidence graphs from input media, governs script generation through evidence constraints, detects complexities across sources, and applies uncertainty handling logic to generate balanced or qualified commentary when conflicts arise. Traceability and audit metadata are embedded directly into the final video output, enabling downstream editorial review, compliance validation, and accountability. Announcement • Jan 20
Avalon Globocare Corp. Announces FDA Registration Renewal for KetoAir Avalon GloboCare Corp. announced the renewal of the U.S. Food and Drug Administration (FDA) establishment registration for the KetoAir device by Qi Diagnostics Limited, a nanosensor-based diagnostic technologies company. Avalon markets and distributes the KetoAir device, a handheld breathalyzer designed for ketogenic health management which is registered with the U.S. Food & Drug Administration under registration number 3026284320. KetoAir is a handheld breathalyzer designed For ketogenic health management and is registered with the U. S. Food and Drug Administration under registration number 30 26284320. The device measures breath acetone concentration (BrAce), a key biomarker associated with fat metabolism and nutritional ketosis. Leveraging advanced nano-sensor technology, KetoAir provides users with real-time, non-invasive insights into metabolic state through breath analysis. The device is intended for individuals pursuing ketogenic diets for weight management, athletic performance, and therapeutic or lifestyle-based ketogenic programs. KetoAir is compatible with both iOS and Android smartphones, with companion applications available through the Apple App Store and Google Play Store. Avalon plans to launch KetoAir in both business-to-business (B2B) and business-to-consumer (B2C) markets via Catch-Up, an automated generative AI-powered software-as-a-service (SaaS) platform for creating short-form video content, operated through its subsidiary Avalon Quantum AI, LLC. This initiative is designed to support and amplify marketing, distribution, and digital engagement initiatives for KetoAir. Board Change • Dec 22
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Lourdes Felix was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Dec 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.5m free cash flow). Negative equity (-US$4.5m). Earnings have declined by 6.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (289% increase in shares outstanding). Market cap is less than US$10m (US$6.21m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (US$1.6m revenue). Announcement • Nov 22
Avalon GloboCare Receives Notice of Non-Compliance with Nasdaq Listing Requirements As previously disclosed, on May 22, 2025, Avalon GloboCare Corp. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company was not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company's stockholders' equity of ($3,891,270), as reported in the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2025,was below the required minimum of $2,500,000, and because, as of May 22, 2025, the Company did not meet the alternative compliance standards, relating to the market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years. The May Nasdaq Letter had no immediate impact on the listing of the Company's common stock, which continued to be listed and traded on The Nasdaq Capital Market, subject to the Company's compliance with the other continued listing requirements. Following the Company's submission of a plan to regain compliance with Listing Rule5550(b)(1), Nasdaq granted the Company an extension of up to 180 calendar days from May 22, 2025, or through November 18, 2025, to regain compliance. On November 19, 2025, the Company received a letter (the November Nasdaq Letter") from Nasdaq indicating that the Company was not in compliance with Listing Rule 5550(b). Unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the Panel"), trading of the Company's common stock would be subject to suspension/delisting. Accordingly, the Company plans to timely request a hearing before the Panel, which request will automatically stay any suspension or delisting action by Nasdaq pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. Announcement • Nov 17
Avalon GloboCare Corp., Annual General Meeting, Dec 30, 2025 Avalon GloboCare Corp., Annual General Meeting, Dec 30, 2025. Reported Earnings • Nov 17
Third quarter 2025 earnings released: US$0.062 loss per share (vs US$1.82 loss in 3Q 2024) Third quarter 2025 results: US$0.062 loss per share (improved from US$1.82 loss in 3Q 2024). Net loss: US$254.3k (loss narrowed 85% from 3Q 2024). New Risk • Sep 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$7.1m). Earnings have declined by 2.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (260% increase in shares outstanding). Market cap is less than US$10m (US$8.90m market cap). Minor Risk Revenue is less than US$5m (US$1.2m revenue). Announcement • Aug 29
Avalon GloboCare to Launch Online Sales of KetoAir Breathalyzer in the United Kingdom Avalon GloboCare Corp. announced that it will launch the sales of KetoAir™ breathalyzer device and related accessories in the United Kingdom (“UK”). The products will be available for purchase starting September 1, 2025. KetoAir™ is a handheld breathalyzer designed for ketogenic health management (U.S. Food and Drug Administration registration number: 3026284320). It measures breath acetone concentration (BrAce), a key indicator of fat metabolism and ketosis. The KetoAir™ breathalyzer device is owned and manufactured by Qi Diagnostics Limited, a nanosensor-based diagnostic technologies company. Intended for users pursuing ketogenic diets for weight loss, athletic performance, or therapeutic purposes, the device utilizes nano-sensor technology to provide real-time insights. KetoAir™ is compatible with both Apple and Android devices and is available via the Apple App Store and Google Play Store. Reported Earnings • Aug 15
Second quarter 2025 earnings released: US$6.22 loss per share (vs US$2.85 loss in 2Q 2024) Second quarter 2025 results: US$6.22 loss per share (further deteriorated from US$2.85 loss in 2Q 2024). Net loss: US$13.5m (loss widened US$11.3m from 2Q 2024). Announcement • Jun 06
Avalon GloboCare Corp. announced that it expects to receive $0.5 million in funding from York Sun Investment Holding Limited Avalon GloboCare Corp. announced that it has entered into a securities purchase agreement with York Sun Investment Holding Limited to issue 141,643 shares of common stock at an issue price of $3.53 per share for gross proceeds of $499,999.79 on June 4, 2025. The closing is anticipated to occur on or before June 6, 2025. A. The company and the buyer are executing and delivering this agreement in reliance upon the exemption from securities registration afforded by section 4(a)(2) of the securities act of 1933, as amended and rule 506(b) promulgated by the United States securities and exchange commission under the 1933 act. Announcement • May 25
Avalon GloboCare Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement On May 22, 2025, Avalon GloboCare Corp. (the ‘Company’) received a letter (the ‘Letter’) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (‘Nasdaq’) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of ($3,891,270), as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2025, was below the required minimum of $2.5 million, and because, as of May 22, 2025, the Company did not meet the alternative compliance standards, relating to the market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years. The Letter has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on The Nasdaq Capital Market, subject to the Company’s compliance with the other continued listing requirements. The Company has 45 calendar days from May 22, 2025, or through Monday, July 7, 2025, to submit to Nasdaq a plan to regain compliance with Listing Rule 5550(b)(1). If Nasdaq accepts the Company’s plan, Nasdaq may grant an extension of up to 180 calendar days from May 22, 2025, or through Tuesday, November 18, 2025, to regain compliance. If Nasdaq does not accept the Company’s plan, the Company will have the right to appeal such decision to a Nasdaq hearings panel. The Company intends to submit to Nasdaq, within the requisite time period, a plan to regain compliance with Listing Rule 5550(b)(1). There can be no assurance that Nasdaq will accept the Company’s plan or that the Company will be able to regain compliance with Listing Rule 5550(b)(1) or maintain compliance with any other Nasdaq requirement in the future. The Company, by filing this Form 8-K, discloses its receipt of the notification from Nasdaq in accordance with Listing Rule 5810(b). Reported Earnings • May 15
First quarter 2025 earnings released: US$1.63 loss per share (vs US$1.86 loss in 1Q 2024) First quarter 2025 results: US$1.63 loss per share. Revenue: US$742.5k (up 76% from 1Q 2024). Net loss: US$2.64m (loss widened 93% from 1Q 2024). Reported Earnings • Apr 01
Full year 2024 earnings released: US$8.44 loss per share (vs US$23.80 loss in FY 2023) Full year 2024 results: US$8.44 loss per share (improved from US$23.80 loss in FY 2023). Net loss: US$7.90m (loss narrowed 53% from FY 2023). Announcement • Mar 11
YOOV Group Holding Limited entered into a definitive merger agreement to acquire Avalon GloboCare Corp. (NasdaqCM:ALBT) in a reverse merger transaction. YOOV Group Holding Limited entered into a definitive merger agreement to acquire Avalon GloboCare Corp. (NasdaqCM:ALBT) in a reverse merger transaction on March 7, 2025. Under the terms of the merger agreement, subject to stockholder approval, on a pro forma basis, post-merger Avalon equityholders are expected to collectively own between approximately 2.5% to 2.2% and YOOV equityholders are expected to collectively own between approximately 97.5%, or 97.8% of the common stock of the combined company on a pro forma basis. The combined company is expected to operate under the name YOOV, Inc. and expected to continue trading on The Nasdaq Capital Market under the symbol “YOOV”. Upon termination of the Merger Agreement under specified circumstances, Avalon may be required to pay YOOV a termination fee of $1.0 million; however, YOOV is not required to pay Avalon a termination fee. Following the merger, Phil Wong will become Chairman, Chief Executive Officer, and President. The merger agreement provides that the board of directors of the combined company will be composed of seven members, with five members initially designated by YOOV and two members initially designated by Avalon.
The transaction is subject to certain closing conditions, including, among other things, (i) approval of the Avalon Stockholder Matters by the requisite Avalon stockholders, (ii) adoption and approval of the Merger Agreement, and the transactions contemplated thereby, by the requisite YOOV shareholders, (iii) the effectiveness of the Registration Statement (iv) the listing of the Avalon Common Stock issuable in connection with the Merger on Nasdaq, (v) all approvals from any Governmental Authority necessary to consummate the transaction and (vi) a written resignation for each of the officers and directors of Avalon GloboCare who are not going to continue as officers or directors of Avalon GloboCare after the Closing. The merger agreement has been unanimously approved by the boards of directors of both companies. The transaction is expected to be completed in the third quarter of 2025. Roth Capital Partners acted as the exclusive financial advisor to Avalon in connection with the merger. Steven Skolnick of Lowenstein Sandler LLP acted as legal advisor for Avalon GloboCare Corp. Joseph M. Lucosky, Scott Linsky and Ian Liao of Lucosky Brookman LLP acted as legal advisor for YOOV Group Holding Limited. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (34% average weekly change). Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$3.67m market cap). Announcement • Nov 22
Avalon GloboCare Regains Compliance with Nasdaq’s Minimum Bid Price Requirement under Nasdaq Rule 5550(a)(2) Avalon GloboCare Corp. announced that the Company received notice from The Nasdaq Stock Market (‘Nasdaq’) on November 19, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2). David Jin, M.D., Ph.D., Chief Executive Officer of Avalon GloboCare, stated, ‘Regaining compliance reflects our commitment to our shareholders and reinforces our focus on strong corporate governance. We remain resolute in our mission to drive sustainable long-term value for both our shareholders and stakeholders’. Reported Earnings • Nov 14
Third quarter 2024 earnings released: US$1.82 loss per share (vs US$2.06 loss in 3Q 2023) Third quarter 2024 results: US$1.82 loss per share. Net loss: US$1.68m (loss widened 13% from 3Q 2023). Announcement • Nov 01
Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific and Clinical Advisory Board Avalon GloboCare Corp. announced that it has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board. Dr. Charles Cavo is the co-founder and Chief Medical Officer of Pounds Transformation, founded to help patients successfully reach their health and wellness goals through a combination of medical and lifestyle interventions related to nutrition and exercise. Dr. Cavo specialized in family medicine as an OBGYN at the Hospital of Central Connecticut and was drawn to the challenge of the obesity epidemic in America and how it negatively affected his patient’s lives.
Dr. Cavo is a member of the board of Obesity Medicine and is board certified in Bariatric Medicine and in Obstetrics & Gynecology. He is also a fellow of the American College of Obstetricians & Gynecologists. Dr. Cavo earned his medical degree from Nova Southeastern University College of Osteopathic Medicine and completed his Obstetrics and Gynecology residency at the University of Connecticut. Announcement • Oct 24
Avalon GloboCare Announces 1-for-15 Reverse Stock Split as Part of Nasdaq Compliance Plan Avalon GloboCare Corp. announced that it will effect a 1-for-15 reverse split of its common shares that will become effective on October 28, 2024. The Company expects that the reverse stock split will allow the Company to regain compliance with the $1.00 minimum bid price requirement of the Nasdaq Capital Market. Avalon GloboCare’s common shares will continue to trade on Nasdaq under the symbol “ALBT” and will begin trading on a split-adjusted basis when the market opens on October 28, 2024. The new CUSIP number for the common shares following the reverse split will be 05344R302. The reverse split will reduce the number of outstanding shares of the Company’s common shares from approximately 16.0 million shares to approximately 1.1 million shares. “This reverse stock split is a strategic step towards regaining compliance with Nasdaq’s listing requirements,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “It will allow us to continue to execute on our business goals and position Avalon GloboCare for long-term growth and success. We remain committed to delivering value to our shareholders through our innovative precision diagnostics and laboratory services". Announcement • Aug 16
Avalon GloboCare Corp., Annual General Meeting, Oct 08, 2024 Avalon GloboCare Corp., Annual General Meeting, Oct 08, 2024. Announcement • Aug 15
Avalon GloboCare Corp. announced delayed 10-Q filing On 08/14/2024, Avalon GloboCare Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Jun 21
Avalon GloboCare Corp. Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference Avalon GloboCare Corp. provided an update on the launch of the KetoAir breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference that was held on May 31 to June 2, 2024 in Austin, Texas. Additionally, there was significant interest from brick-and-mortar retailers, key opinion leaders (KOLs), and influencers. At the conference, the company introduced the Zero to Keto program for health and keto coaches and announced that The company expects to start taking retail sales orders from consumers later this month, once the first shipment arrives at U.S. distribution center. The FDA-registered KetoAir breathalyzer empowers users to take control of their health and wellness journey. Utilizing advanced breath testing nano-technology, aligned with the app's AI nutritionist, it offers personalized nutritional and exercise recommendations tailored to individual health goals. The company believes this novel feature sets a new standard in the market, providing users with a holistic solution to monitor and optimize their ketosis state and body fat burning rate. The "Blow to Know" technology aims to deliver precise and immediate results achievable with a single exhale, empowering users to monitor how various foods and activities influence their ketone levels. Announcement • May 25
Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024 Avalon GloboCare Corp. (‘Avalon’ or the ‘Company’) announced that it received a notice (the ‘Notice’) on May 22, 2024 from The Nasdaq Stock Market LLC (‘Nasdaq’) stating that the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the ‘Listing Rule’) because the Company has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (the ‘Quarterly Report’) with the Securities and Exchange Commission (the ‘SEC’). The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market. The Notice states that the Company has 60 calendar days from the date of the Notice, or July 22, 2024, to submit a plan to regain compliance with the Listing Rule. If Nasdaq accepts the Company’s plan to regain compliance, then Nasdaq may grant the Company up to 180 calendar days from the prescribed due date of the Quarterly Report, or November 18, 2024, to file the Quarterly Report to regain compliance. The Company continues to work diligently to finalize its Quarterly Report and plans to file its Quarterly Report as promptly as possible to regain compliance with the Listing Rule. This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. Announcement • May 17
Avalon GloboCare Corp. announced delayed 10-Q filing On 05/15/2024, Avalon GloboCare Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • May 09
The Nasdaq Stock Market, LLC Grants Avalon GloboCare a 180-Day Extension to October 28, 2024 to Regain Compliance with the Minimum Bid Price Requirement On May 2, 2024, Avalon GloboCare Corp. (the ‘Company’) received a letter from the Nasdaq Stock Market, LLC (‘Nasdaq’) advising that the Company had been granted a 180-day extension to October 28, 2024, to regain compliance with the Minimum Bid Price Requirement. As previously reported, on November 3, 2023, the Company received written notice (the ‘Notice’) from the Nasdaq Stock Market, LLC that the closing bid price for the Company’s common stock, par value $0.0001 per share (the ‘Common Stock’), had been below $1.00 per share for the previous 30 consecutive business days, and that the Company is therefore not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market as set in Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Requirement’). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a grace period of 180 calendar days, or until May 1, 2024, to regain compliance with the Minimum Bid Price Requirement. The Company will continue to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including but not limited to, implementing a reverse stock split of its Common Stock, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period, Nasdaq will provide notice that the Company’s Common Stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during this 180-day extension. Announcement • Apr 23
Avalon GloboCare Corp. Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference Avalon GloboCare Corp. announced the official launch of the KetoAir breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference being held from May 31 to June 2, 2024 in Austin, Texas. KetoAir is a cutting-edge breathalyzer featuring Hot App shareable technology with AI-enabled software, specifically engineered for ketogenic health management. By leveraging the nano-sensor-based technology and AI algorithms, the Keto Air™ breathalyzer is designed not only to assess the ketosis status of its individual user but to also seamlessly record diet and exercise details directly into the KetoAir app, accessible on both the Apple App Store and Google Play Store. The FDA-registered KetoAir breathyzer empowers users to take control of their health and wellness journey. Utilizing advanced breath testing nano-technology, aligned with the app's AI nutritionist, it offers personalised nutritional and exercise recommendations tailored to individual health goals. The Company believes this novel feature sets a new standard in the market, providing users with a holistic solution to monitor and optimize their ketosis state and body fat burning rate. The "Blow to Know" technology aims to deliver precise and immediate results achievable with a single exhale, empowering users to monitor how various foods and activities influence their ketone levels. The Company previously announced its plans to commercialize the product and has now taken the final steps towards initiating sales of the KetoAir breathalyzer. The Company believes the KetoAir airalyzer will fill a gap in the market with a non-invasive daily test that will hold a competitive edge due to its improved precision and effectiveness. Following its launch, consumers will be able to buy the KetoAir™ Breathalyzer exclusively at the newly designed website KetoAir.com. Announcement • Apr 02
Avalon GloboCare Corp. announced delayed annual 10-K filing On 04/01/2024, Avalon GloboCare Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Reported Earnings • Nov 17
Third quarter 2023 earnings released: US$0.14 loss per share (vs US$0.56 loss in 3Q 2022) Third quarter 2023 results: US$0.14 loss per share (improved from US$0.56 loss in 3Q 2022). Net loss: US$1.49m (loss narrowed 73% from 3Q 2022). Announcement • Nov 10
Avalon Globocare Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market as Set Forth in Nasdaq Listing Rule 5550(a)(2) On November 3, 2023, Avalon GloboCare Corp. (the ‘Company’) received written notice (the ‘Notice’) from the Nasdaq Stock Market, LLC (‘Nasdaq’) that the closing bid price for the Company’s common stock had been below $1.00 per share for the previous 30 consecutive business days, and that the Company is therefore not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market. In accordance with the Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until May 1, 2024, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period. If the Company is not in compliance by May 1, 2024, the Company may qualify for a second 180 calendar day compliance period. If the Company does not qualify for, or fails to regain compliance during the second compliance period, then Nasdaq will notify the Company of its determination to delist its common stock, at which point the Company would have an option to appeal the delisting determination to a Nasdaq hearings panel. The Company intends to actively monitor the closing bid price of its common stock and may, if appropriate, consider implementing available strategies to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules. New Risk • Oct 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 1.7% per year over the past 5 years. Market cap is less than US$10m (US$9.42m market cap). Minor Risks Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Revenue is less than US$5m (US$1.1m revenue). Announcement • Sep 09
Avalon GloboCare Corp., Annual General Meeting, Oct 12, 2023 Avalon GloboCare Corp., Annual General Meeting, Oct 12, 2023, at 11:00 US Eastern Standard Time. Agenda: To elect seven director nominees to serve as directors until the next annual meeting of stockholders and until their successors are duly elected and qualified; to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023; to approve Amended and Restated 2020 Stock Incentive Plan; to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in this Proxy Statement; to vote, on an advisory basis, on how often we will conduct an advisory vote on the compensation of named executive officers (every year, every two years or every three years); and to consider any other matters that may properly come before the Annual Meeting. Reported Earnings • Aug 16
Second quarter 2023 earnings released: US$0.25 loss per share (vs US$0.23 loss in 2Q 2022) Second quarter 2023 results: US$0.25 loss per share (further deteriorated from US$0.23 loss in 2Q 2022). Net loss: US$2.54m (loss widened 25% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Announcement • May 17
Avalon GloboCare Corp. announced delayed 10-Q filing On 05/16/2023, Avalon GloboCare Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Reported Earnings • Apr 02
Full year 2022 earnings released: US$1.28 loss per share (vs US$1.07 loss in FY 2021) Full year 2022 results: US$1.28 loss per share (further deteriorated from US$1.07 loss in FY 2021). Net loss: US$11.9m (loss widened 31% from FY 2021). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Announcement • Feb 14
Avalon GloboCare Corp. announced that it expects to receive $11 million in funding Avalon GloboCare Corp. announced that it has entered into a securities purchase agreement for series B preferred stock for gross proceeds of $11 million on February 13, 2023. The shares are convertible into shares at a fixed conversion price of $3.78 per share. Announcement • Jan 24
Avalon GloboCare Regains Compliance with the Minimum Bid Requirement As previously reported, on February 9, 2022, Avalon GloboCare Corp. (the ‘Company’) received a letter from the Listing Qualifications Staff (the ‘Staff’) of the Nasdaq Stock Market LLC (‘Nasdaq’) indicating that the bid price of the Company's common stock (the ‘Common Stock’), had closed below $1.00 per share for 30 consecutive business days and, as a result, the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth the minimum bid price requirement for continued listing (the ‘Minimum Bid Requirement’). On January 20, 2023, the company received a letter from the Staff of Nasdaq indicating that it has regained compliance with the Minimum Bid Requirement and this matter is now closed. Announcement • Jan 12
Avalon Globocare Appoints Lourdes Felix, to Its Board of Directors Avalon GloboCare Corp. announced that it has appointed Lourdes Felix to its Board of Directors. Lourdes Felix is an entrepreneur and corporate finance executive with 30 years of combined experience in capital markets, public accounting and in the private sector. She presently serves as Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., a leader in addiction treatment solutions and related disorders. She has been with BioCorRx since October 2012. Ms. Felix is one of the founders and President of BioCorRx Pharmaceuticals Inc., a majority owned subsidiary of BioCorRx Inc. She has been instrumental in capital procurement, completing multi-million dollar equity financings, and is accomplished in structuring and negotiating transactions. Along with other executives of the company, Ms. Felix restructured and expanded the business model to position it for long term growth in the addiction treatment space and drug development. She also has extensive experience with clinic operations management. Prior to joining BioCorRx, her experience was in the private sector and public accounting. She has expertise in finance, accounting, company-wide operations, budgeting, and internal control principles including GAAP, SEC, and SOX Compliance. She has thorough knowledge of federal and state regulations and has successfully managed and produced SEC regulatory filings. She also has extensive experience in developing and managing financial operations. Lourdes holds a Bachelor of Science degree in Accounting from the University of Phoenix. She continued her education and is an MBA candidate at D’Amore-McKim School of Business, Northeastern University. Announcement • Nov 22
Avalon GloboCare Corp., Annual General Meeting, Dec 29, 2022 Avalon GloboCare Corp., Annual General Meeting, Dec 29, 2022, at 11:00 Eastern Standard Time. Agenda: To elect the six director nominees named in the Proxy Statement to hold office until the next annual meeting of stockholders and until their successors are duly elected and qualified; To ratify the appointment of Marcum LLP as the Company’s independent auditors for the fiscal year ending December 31, 2022; and To act on such other matters as may properly come before the meeting or any adjournment thereof. Reported Earnings • Nov 16
Third quarter 2022 earnings released: US$0.056 loss per share (vs US$0.024 loss in 3Q 2021) Third quarter 2022 results: US$0.056 loss per share (further deteriorated from US$0.024 loss in 3Q 2021). Revenue: US$317.4k (down 33% from 3Q 2021). Net loss: US$5.41m (loss widened 168% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Scientific & Clinical Advisory Board Bob Langer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Nov 09
Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into an agreement to acquire 60% stake in Laboratory Services MSO, LLC for $31 million. Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into an agreement to acquire 60% stake in Laboratory Services MSO, LLC for $31 million on November 7, 2022. The consideration consisted of $5 million was paid as a refundable prepayment at signing, (ii) $10 million will be paid in cash at the closing, (iii) $15 million will be paid pursuant to the issuance of 15,000 shares of the Company’s newly designated Series B Convertible Preferred Stock, stated value $1,000, which Series B Preferred Stock will be convertible into shares of the Company’s common stock at a conversion price per share equal to $0.575 or an aggregate of 26,086,957 shares of the Company’s common stock, which are subject to the Lock Up Period, $1 million will be paid on the first anniversary of the closing date. The Seller is also eligible to receive certain earnout payments upon achievement of certain operating results, which may be comprised of up to $10 million of which (x) $5 million will be paid in cash and (y) $5 million will be paid pursuant to the issuance of the number of shares of Company common stock valued at $5 million. The Cash Earnout Payment, upon the Company achieving total combined EBITDA equal to or greater than $20 Million for the two (2) fiscal years ending December 31, 2022 and 2023 as recorded on the Company’s audited consolidated financial statements. The Equity Earnout Payment, upon the Company achieving total combined EBITDA equal to or greater than $28 Million for the two (2) fiscal years ending December 31, 2022 and 2023 as recorded on the Company’s audited consolidated financial statements.
In connection with the closing of the Transaction, Sarah Cox will become the Chief Operating Officer of the Company, replacing Meng Li, who will continue to serve as a Chief Operating Officer of Avalon (Shanghai) Healthcare Technology Co., Ltd, a subsidiary of the Company. In addition, Ms. Cox will be appointed as a director of the Company and Ms. Li will resign as a director of Avalon GloboCare. At the closing of the Transaction, Ms. Cox and the Company will enter into an employment agreement providing for an annual salary of three hundred and fifty thousand dollars $0.35 million and other customary compensation.
In conjunction with the Transaction, on November 7, 2022, the Company conducted a private placement offering of 5,000 shares of its newly designated Series A Convertible Preferred Stock. The closing of the Transaction is subject to customary conditions to closing, including completion of financing for the remainder of the cash purchase price. The closing of the transactions contemplated by the Agreement is subject to customary conditions to closing, including completion of financing for the remainder of the cash purchase price. The transaction is expected to close in 30 days, subject to a 90 day right of extension by the Company.
Steven Skolnick and Annie Nazarian Davydov of Lowenstein Sandler LLP acted as legal advisor to Avalon GloboCare. Michael S. Winsten of Winsten Law Group acted as legal advisor to Laboratory Services. Revere Securities LLC is acting as an advisor to Avalon in the transaction. Lowenstein Sandler LLP is acting as legal counsel to Avalon in the transaction. Blythe Global LLC is acting as the accounting advisor. Announcement • Aug 12
Avalon GloboCare Receives Second Letter from the Staff of Nasdaq As previously reported, on February 9, 2022, Avalon GloboCare Corp., received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LbLC (“Nasdaq”) therein indicating that, based upon the closing bid price of the Company’s common stock (the “Common Stock”) for the prior 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was granted 180 calendar days, or until August 8, 2022, to regain compliance. On August 9, 2022, the Company received a second letter from the Staff advising that the Company had been granted an additional 180 calendar days, or to February 6, 2023, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company will continue to monitor the closing bid price of its Common Stock and seek to regain compliance with the Minimum Bid Price Requirement within the allotted compliance period. If the Company does not regain compliance within the allotted compliance period, Nasdaq will provide notice that the Company’s Common Stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the 180-day extension. Reported Earnings • Aug 06
Second quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 2Q 2021) Second quarter 2022 results: US$0.023 loss per share (up from US$0.028 loss in 2Q 2021). Revenue: US$290.8k (up 9.8% from 2Q 2021). Net loss: US$2.03m (loss narrowed 14% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Announcement • Jul 01
Avalon GloboCare Corp. Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer Avalon GloboCare Corp. announced a new study applying artificial intelligence (AI) enhanced protein design QTY Code technology. The method is expected to accelerate development of therapeutic monoclonal antibodies to treat cancer. The research demonstrates a novel method for quickly predicting the design of so-called water-loving or hydrophilic variant structures of the 14 glucose transport membrane proteins in cells, which allows researchers to study the proteins more easily in water. Glucose transport membrane proteins are deregulated in many tumor types and are a potentially important target for cancer therapy. The study was published on June 27, 2022, in QRB Discovery, a peer-reviewed, research journal of biological function, structure and mechanism. The QTY Code breakthrough technology, developed by Avalon and the laboratory of Dr. Shuguang Zhang, Ph.D., of MIT’s Media lab in Boston, MA, is a protein-design platform that can turn water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their use in many clinical applications, including drug development. A team of scientists led by Dr. Zhang applied the QTY code to the 14 glucose transport membrane proteins that transport sugar to cells. They used Google’s AlphaFold2, a DeepMind AI program, which can accurately and quickly predict how proteins fold. Dr. Zhang and his team used the QTY code with the open-source AlphaFold2 to predict the structures of these proteins in both their natural hydrophobic shapes and their QTY-code altered water-soluble shapes. Authors of the QRB Discovery paper include Dr. Zhang and Eva Smorodina, an undergraduate intern-student in structural biology in the Greiff Lab at the University of Oslo; Drs. Fei Tao and Rui Qing of the Shanghai Jiaotong University (Dr. Qing was previously a postdoctoral researcher in the MIT Media Lab and later a research scientist at the Koch Institute for Integrative Cancer Research at MIT); Dr. Steve Yang, an MIT alumnus and now at PT Metiska Farma in Indonesia; and Dr. David Jin, M.D., Ph.D. of Avalon GloboCare Corp., whose collaboration helped drive Dr. Zhang’s research in applying the QTY code to the study of cancer cells. Avalon GloboCare funded the research. Announcement • Jun 09
Avalon GloboCare Corp. announced that it has received $3.718943 million in funding On June 8, 2022, Avalon GloboCare Corp. closed the transaction. The company amended the terms of the transaction. The company has issued convertible note for gross proceeds of $3,718,942.74 and 2022 warrant to acquire an aggregate of 1,239,647 shares of common stock. The 2022 Warrants will be exercisable for five years at an exercise price of $1.25. Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Scientific & Clinical Advisory Board Bob Langer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • May 19
Avalon GloboCare Corp. Appoints Hongxing Liu to Scientific and Clinical Advisory Board Avalon GloboCare Corp. announced that the Company has signed a memorandum of understanding with Lu Daopei Hematology Institute to co-develop precision companion diagnostics (CDx) for chimeric antigen receptor (CAR)-T cell therapies. To further strengthen its CDx development capabilities, Avalon has appointed Dr. Hongxing Liu, M.D., M.S., Executive President of LDHI and a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board. Reported Earnings • May 13
First quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 1Q 2021) First quarter 2022 results: US$0.023 loss per share (up from US$0.028 loss in 1Q 2021). Revenue: US$297.6k (up 9.7% from 1Q 2021). Net loss: US$2.07m (loss narrowed 13% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Board Change • May 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Scientific & Clinical Advisory Board Bob Langer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Apr 01
Full year 2021 earnings released: US$0.11 loss per share (vs US$0.16 loss in FY 2020) Full year 2021 results: US$0.11 loss per share (up from US$0.16 loss in FY 2020). Revenue: US$1.39m (up 4.9% from FY 2020). Net loss: US$9.09m (loss narrowed 28% from FY 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. Announcement • Feb 15
Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies Avalon GloboCare Corp. announced that the Company is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor " Natural Killer (CAR-NK) cell therapies. Natural killer (NK) cells constitute an important component of the immune system. NK cells seek out abnormal cells, including cancerous cells, and destroy them. However, cancer cells are often capable of “masking” themselves to evade attack by NK cells. By adding a “Chimeric Antigen Receptor” (CAR) to a patient’s own or universal-donor NK cells, these engineered CAR-NK cells are designed to “unmask,” recognize and destroy a patient’s specific tumor surface targets. Avalon is leveraging its mRNA-based FLASH-CAR™ platform to develop autologous and universal (“off-the-shelf”) CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors. Avalon plans to expand its clinical program in collaboration with its major clinical trial partner, the Lu Daopei Hospital. The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon’s lead CAR-T candidate, part of the Company’s proprietary mRNA-based FLASH-CAR™ platform. AVA-011 is currently at the IND-enabling, process development stage, which is expected to produce clinical-grade CAR-T cells for an upcoming clinical trial in patients with hematological malignancies. The platform uses next generation CAR technology to modify patients’ T or universal-donor NK cells using a ribonucleic acid (RNA)-based platform rather than a viral vector, allowing for more rapid and lower-cost bio-manufacturing of the cell therapy products. Reported Earnings • Nov 18
Third quarter 2021 earnings released: US$0.024 loss per share (vs US$0.04 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$486.8k (up 57% from 3Q 2020). Net loss: US$2.02m (loss narrowed 38% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings. Director Overboarding • Sep 14
Director William Stilley has joined 3rd company board Independent Director William Stilley has been appointed to the board of Sysorex, Inc. (OTCPK:SYSX). Stilley now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Adial Pharmaceuticals, Inc. (NasdaqCM:ADIL), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model. Reported Earnings • Aug 18
Second quarter 2021 earnings released: US$0.028 loss per share (vs US$0.039 loss in 2Q 2020) The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: US$280.2k (down 3.3% from 2Q 2020). Net loss: US$2.36m (loss narrowed 23% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings. Announcement • Jun 16
Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into a definitive agreement to acquire Hebei Senlang Biotechnology Inc., Ltd. for approximately CNY 640 million. Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into a definitive agreement to acquire Hebei Senlang Biotechnology Inc., Ltd. for approximately CNY 640 million on June 13, 2021. As part of the consideration, Avalon GloboCare will issue 81 million shares of its common stock. SenlangBio will continue to maintain operations in the Shijiazhuang High-tech Development Zone, Hebei Province, China. Upon completion of the acquisition, David Jin will continue to serve as President and Chief Executive Officer of Avalon GloboCare, as well as co-Chief Executive Office of the SenlangBio subsidiary. Jianqiang Li Scientific Founder and CSO of SenlangBio will join the Board of Directors of Avalon. Li will also become Chief Technical Officer of Avalon. Avalon will continue to maintain its corporate headquarters in Freehold, New Jersey, United States. VStock Transfer, LLC acted as escrow agent in the transaction pursuant to which Avalon will deposit equal to ten percent shares that is 8.1 million with VStock. The closing of the acquisition is subject to various conditions to closing set forth in the acquisition agreement, including the contemporaneous closing of the Equity Financing as well as Avalon stockholder approval, and any SEC review of the proxy statement being filed in connection with the annual meeting of shareholders and Nasdaq approvals. Steven M. Skolnick of Lowenstein Sandler LLP, Jun He Law and Goodwin Procter acted as legal advisors while Friedman LLP and Marcum LLP acted as accountant to Avalon GloboCare in the transaction. CEC Capital Group acted as financial advisor while Crescendo Communications represented Avalon GloboCare in the transaction. Jin Yuan of Co-Effort LLP acted as legal advisor to Hebei Senlang Biotechnology in the transaction. Reported Earnings • May 16
First quarter 2021 earnings released: US$0.028 loss per share (vs US$0.043 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses and improved control over expenses, although revenues were flat. First quarter 2021 results: Revenue: US$289.8k (flat on 1Q 2020). Net loss: US$2.37m (loss narrowed 28% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 02
Full year 2020 earnings released: US$0.16 loss per share (vs US$0.24 loss in FY 2019) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: US$1.33m (down 11% from FY 2019). Net loss: US$12.7m (loss narrowed 30% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 17
New 90-day high: US$1.59 The company is up 34% from its price of US$1.19 on 18 November 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 1.0% over the same period. Is New 90 Day High Low • Jan 26
New 90-day high: US$1.33 The company is up 17% from its price of US$1.14 on 27 October 2020. The American market is also up 17% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Healthcare industry, which is up 14% over the same period. Reported Earnings • Nov 11
Third quarter 2020 earnings released: US$0.04 loss per share The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2020 results: Revenue: US$325.0k (down 9.2% from 3Q 2019). Net loss: US$3.25m (loss narrowed 16% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. 